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Abstract
Introduction: Immunological studies of giant cell arteritis (GCA) suggest that a triggering antigen of unknown
nature could generate a specific immune response. We thus decided to detect autoantibodies directed against
endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) in the serum of GCA patients and to identify their
target antigens.
Methods: Sera from 15 GCA patients were tested in 5 pools of 3 patients’ sera and compared to a sera pool from
12 healthy controls (HCs). Serum immunoglobulin G (IgG) reactivity was analysed by 2-D electrophoresis and
immunoblotting with antigens from human umbilical vein ECs (HUVECs) and mammary artery VSMCs. Target
antigens were identified by mass spectrometry.
Results: Serum IgG from GCA patients recognised 162 ± 3 (mean ± SD) and 100 ± 17 (mean ± SD) protein spots
from HUVECs and VSMCs, respectively, and that from HCs recognised 79 and 94 protein spots, respectively. In total,
30 spots from HUVECs and 19 from VSMCs were recognised by at least two-thirds and three-fifths, respectively, of
the pools of sera from GCA patients and not by sera from HCs. Among identified proteins, we found vinculin,
lamin A/C, voltage-dependent anion-selective channel protein 2, annexin V and other proteins involved in cell
energy metabolism and key cellular pathways. Ingenuity pathway analysis revealed that most identified target
antigens interacted with growth factor receptor-bound protein 2.
Conclusions: IgG antibodies to proteins in the proteome of ECs and VSMCs are present in the sera of GCA
patients and recognise cellular targets that play key roles in cell biology and maintenance of homeostasis. Their
potential pathogenic role remains to be determined.
Introduction
Giant cell arteritis (GCA), also known as temporal arter-
itis, is a primary systemic vasculitis involving large- and
medium-sized vessels. GCA commonly causes bitem-
poral headaches, jaw claudication, scalp tenderness and/
or abnormal temporal arteries (tender, nodular, swollen
and thickened arteries with decreased pulses) detected
during physical examinations. GCA does not occur in
people younger than 50 years old, and its incidence
increases with age and peaks in Caucasians older than
70 years of age [1,2]. Ocular ischaemic complications
occur in 25% of the patients and leads to irreversible
visual loss in 15% [3]. No definite immunological mar-
ker has been identified in GCA, and patients usually
present with increased erythrocyte sedimentation rates
and/or C-reactive protein levels. Diagnosing GCA can
be difficult, and temporal artery biopsy is the gold stan-
dard for making the diagnosis [4]. However, in 10% to
20% of patients with GCA, the biopsy shows no specific
change [5].
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GCA is an inflammatory condition of unknown origin
characterised by the presence of giant cells and a remo-
delling process in the arterial wall [6]. In patients with
GCA, an immune-mediated reaction is suspected to be
triggered by an antigen of unknown origin, either micro-
bial or a self-antigen, that could be presented to T cells
by dendritic cells [7]. Thus, macrophages and giant cells
stimulated by interferon-g (IFN-g) play a major role in
the disruption of the elastic lamina and the remodelling
of vessel walls. In addition, in the adventitia, macro-
phages produce proinflammatory cytokines such as
interleukin 1 (IL-1) and IL-6, whereas in the media and
intima they contribute to arterial injury by producing
metalloproteinases and nitric oxide [6,8,9].
Anti-endothelial cell (anti-EC) antibodies (AECAs)
have been detected in a wide range of systemic inflam-
matory and/or autoimmune diseases, including primary
and/or secondary systemic vasculitis [10]. Although the
pathogenic role of AECAs remains controversial [11,12],
these antibodies may be responsible for EC activation
[13] and induction of antibody-dependent, cell-mediated
cytotoxicity and apoptosis [14]. In GCA, AECAs were
detected in 33% of sera by performing ELISA on fixed
human umbilical vein ECs (HUVECs) [15], but their
presence was not confirmed by indirect immunofluores-
cence [16]. Anti-vascular smooth muscle cell (anti-
VSMC) antibodies have been detected in an experimen-
tal rat model of vasculitis [17]; however, to our knowl-
edge, these antibodies have not been investigated in
patients with primary systemic vasculitis.
We used 1-D and 2-D immunoblotting, followed by
mass spectrometry (MS), to investigate the presence of
autoantibodies directed against ECs and VSMCs and
identify their target antigens in patients with GCA.
Materials and methods
Patients
Serum samples were obtained from 15 patients who ful-
filled the American College of Rheumatology (ACR) cri-
teria for GCA [4] and 33 patients with anti-neutrophil
cytoplasm antibody (ANCA)-associated vasculitis who
fulfilled the ACR and the Chapel Hill criteria used as
vasculitis controls, with the control group comprising 15
patients with Wegener’s granulomatosis (WG), 9 with
Churg-Strauss syndrome (CSS) and 9 with microscopic
polyangiitis (MPA) [18]. In each group of patients with
ANCA-associated vasculitis, two-thirds of the patients
had active disease as assessed by a Birmingham Vasculi-
tis Activity Score (BVAS) >3 in the absence of treat-
ment, and one-third of the patients had inactive disease
as assessed by a BVAS <3. Some patients in both groups
either received corticosteroids and/or immunsuppres-
sants at the time of blood sampling. Sera from 12
healthy blood donors were used as healthy controls
(HCs). Serum samples were collected from patients and
HCs, aliquoted and stored at -80°C until use. Serum
samples were used individually for 1-D immunoblotting
and pooled for 2-D immunoblotting (five pools of sera
from three patients with GCA each, and one pool of
sera from twelve HCs). All patients and healthy controls
gave their written informed consent to participate in the
study. Serum samples were collected with the approval
of the ethics committee of the groupe hospitalier Pitié-
Salpêtrière, and the study conformed to the principles
outlined in the Declaration of Helsinki.
Cell culture
Human internal mammary artery VSMCs were obtained
from patients undergoing aortocoronary bypass surgery.
All patients gave their written consent, and the protocol
for waste surgical tissue was approved by the ethics
committee of groupe hospitalier Pitié-Salpêtrière. These
cells were immortalised by transduction of a lentiviral
vector incorporating the catalytic subunit of the human
holoenzyme telomerase RT and T antigen of simian
virus 40 in a primary culture of VSMCs as previously
described [19]. Immortalised VSMCs were cultured in
Smooth Muscle Cell Basal Medium (PromoCell, Heidel-
berg, Germany) supplemented with decomplemented
FCS (5%), insulin (5 μg/mL), basic fibroblast growth fac-
tor (bFGF) (2 ng/mL), epidermal growth factor (EGF)
(0.5 ng/ml), streptomycin/penicillin (1%) and ciprofloxa-
cin (1%) at 37°C in 5% CO2. The VSMC phenotype was
confirmed by using smooth muscle myosin heavy chains
1 and 2 and sm22a antibodies (Abcam, Cambridge, UK)
(data not shown).
HUVECs were isolated from sterile, freshly obtained
umbilical cords at the time of a normal delivery by
using 15 mg/mL collagenase type I digestion as pre-
viously described [20,21]. All donors gave their written
consent. HUVECs were cultured with EC medium (Pro-
moCell) supplemented with decomplemented FCS (2%),
bFGF (1 ng/mL), EGF (0.1 ng/mL), EC growth supple-
ment/heparin (0.4%), hydrocortisone (1 μg/mL), strepto-
mycin/penicillin (1%) and ciprofloxacin (1%) at 37°C in
5% CO2. HUVECs from four donors were harvested
after the third passage to perform protein extraction.
One-dimensional immunoblotting
Confluent VSMCs were detached with the use of 0.05%
trypsin and 0.53 mM ethylenediaminetetraacetic acid.
Protein extract was obtained by use of a 125 mM Tris,
pH 6.8, solution containing 4% SDS, 1.45 M b-mercap-
toethanol, 1 μg/mL aprotinin, 1 μg/mL leupeptin, 1 μg/
mL pepstatin and 1 mM phenylmethylsulphonyl fluoride
(PMSF). Protein extract was then sonicated four times
for 30 seconds each and boiled. In total, 120 μL of solu-
bilised proteins were separated by electrophoresis on
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10% SDS-PAGE gels (Bio-Rad Laboratories, Hercules,
CA, USA), transferred onto nitrocellulose membranes
by using a semidry electroblotter (model A; Ancos,
Hojby, Denmark) and incubated with sera from patients
with GCA, WG, CSS and MPA or from healthy donors
at a 1:100 dilution overnight at 4°C with the Cassette
Miniblot System (Immunetics Inc., Cambridge, MA,
USA). Detection of IgG reactivity was carried out as
previously reported [22-24] (Additional file 1) with the
use of a g-chain-specific secondary rabbit anti-human
IgG antibody coupled to alkaline phosphatase. Immu-
noreactivity was revealed by Nitro Blue Tetrazolium/5-
bromo-4-chloro-3-indolyl phosphate staining (Sigma-
Aldrich, St. Louis, MO, USA) as previously reported
[23,24] (Additional file 1) and quantified by densitome-
try in reflective mode (Epson Perfection 1200 S densit-
ometer; Seiko Epson Corp., Nagano-ken, Japan) and
scanned again to quantify transferred proteins [23,24].
Two-dimensional immunoblotting
Protein extracts
HUVECs and VSMCs were stored at -80°C in 1 mM
PMSF and protease inhibitors (Complete Mini; Roche
Diagnostics, Meylan, France). Protein extraction was
performed as described previously [25] (Additional file
1). Briefly, cells were suspended at 1 × 106/mL in a sam-
ple solution extraction kit (Kit 3; Bio-Rad Laboratories).
Cell samples were sonicated, and the supernatant was
collected after ultracentrifugation (Optima L90-K ultra-
centrifuge; Beckman Coulter, Fullerton, CA, USA) at
150,000 × g for 25 minutes at 4°C. Protein quantification
was carried out using the Lowry method [26]. The
supernatant was aliquoted and stored at -80°C.
Two-dimensional electrophoresis
Two-dimensional electrophoresis (2-DE), 2-D immuno-
blotting and protein identification by MS were per-
formed as previously reported [27] and are detailed in
Additional file 1.
Modelling with the use of ingenuity pathway analysis
software
To gain insight into the biological pathways and net-
works that were significantly represented in our proteo-
mic data sets, we used ingenuity pathway analysis
software (IPA; Ingenuity Systems, Redwood City, CA,
USA). IPA selects ‘focus proteins’ to be used for gener-
ating biological networks. Focus proteins are the pro-
teins from data sets that are mapped to corresponding
gene objects in the Ingenuity Pathway Knowledgebase
(IPKB) and are known to interact with other proteins on
the basis of published, peer-reviewed content in the
IPKB. From these interactions, IPA builds networks with
a size of no more than 35 genes or proteins. A P value
for each network is calculated according to the fit of the
user’s set of significant genes and/or proteins. IPA com-
putes a score for each network from the P value that
indicates the likelihood of the focus proteins in a net-
work being found together by chance. We selected only
networks scoring ≥ 2 with P < 0.01 of not being gener-
ated by chance. Biological functions were assigned to
each network by use of annotations from the scientific
literature and stored in the IPKB. Fisher’s exact test was
used to calculate the P value to determine the probabil-
ity of each biological function and/or disease or pathway
being assigned by chance. We used P ≤ 0.05 to select
highly significant biological functions and pathways
represented in our proteomic data sets. The build func-
tion of IPA allows the generation of pathways that can
complete the data analysis by showing interactions of
identified proteins with a specific group of molecules
[28,29].
Results
The clinical and histological characteristics of patients
with GCA are summarised in Additional file 2, Supple-
mental Table S1. The mean age (± SD) of the patients
with GCA was 74.8 ± 8.15 years. Among the 15 patients
(5 men), 13 had histological evidence of GCA. All the
15 patients had active disease at the time of blood sam-
pling: twelve were included at the time of diagnosis, two
experienced a disease relapse and another one had an
acute flare while being treated with prednisone. None of
the other 14 patients were taking corticosteroids at the
time of blood sampling.
One-dimensional immunoblotting of IgG reactivity
against VSMC protein extracts
One-dimensional immunoblots of IgG reactivity were
analysed with VSMC protein extracts in sera from
patients with GCA; control patients with ANCA-asso-
ciated vasculitis, including those with WG, MPA and
CSS; and HCs. All subjects tested expressed an IgG
reactivity band directed against a 45-kDa protein. In
patients with GCA, a number of IgG reactivities were
expressed that were not identified in patients with
ANCA-associated vasculitis or in HCs, including reactiv-
ities directed against protein bands of 85 kDa (Addi-
tional file 3).
Two-dimensional immunoblotting of IgG reactivity
against VSMC protein extracts
The proteome of VSMCs contained 1,427 different pro-
teins ranging from 3 to 10 isoelectrofocalisation points
(IPs) and from 10 to 250 kDa. Among those, a mean (±
SD) of 679 ± 258 protein spots were detected after
being transferred onto polyvinylidene fluoride (PVDF)
membranes. Serum IgG from the HC pool recognised
94 protein spots, whereas IgG from the 5 pools from
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GCA patients recognised a mean (± SD) of 100 ± 17
protein spots corresponding to a total of 268 different
protein spots. Most of these 268 protein spots were
recognised from only 1 or 2 pools from patients with
GCA and/or from the HC pool. Among these protein
spots, 29 were recognised by at least three-fifths of the
pools from GCA patients, including 19 not recognised
by the HC pool (Additional file 4, Supplemental Table
S2). These 19 protein spots were identified by MS as
detailed in Table 1 and Additional file 5. The localisa-
tions of identified protein spots in the analytical gel are
depicted in Figure 1. Among these proteins, only one,
the far upstream element-binding protein 2 (FUBP2)
(Figure 2), was recognised in all five pools of sera from
Table 1 Mass spectrometry data of vascular smooth muscle cell protein spots identified as specific target antigena
Spot
ID
Protein SwissProt
accession
number
Theoretical/
estimated MW,
kDa
Theoretical/
estimated
pI
Number of
unique identified
peptidesc, d
Total
ion
scored
Best
ion
scored
Sequence
coverage,
%d
173 Vinculin [Swiss Prot:
VINC_HUMAN]
124/122 5.5/6.4 3/14 39 19 19
294 Putative heat shock protein
HSP90, subunit a2
b
[Swiss Prot:
HS902_HUMAN]
39/94 4.6/5.6 1/5 40 40 22
340 Far upstream element-
binding protein 2
[Swiss Prot:
FUBP2_HUMAN]
73/88 6.8/7.2 4-2/10-9 67-46 24-32 21-16
341 Far upstream element-
binding protein 2
[Swiss Prot:
FUBP2_HUMAN]
73/88 6.8/7.4 5-5/12-11 84-119 24-35 25-19
344 Far upstream element-
binding protein 2
[Swiss Prot:
FUBP2_HUMAN]
73/88 6.8/7.8 4/11 85 37 22
580 Lamin A/Cb [Swiss Prot:
LMNA_HUMAN]
74/67 6.6/6.5 1/10 24 24 16
Coatomer subunit ab [Swiss Prot:
COPA_HUMAN]
138/67 7.7/6.5 1/3 37 37 3
598 UDP-glucose 6-
dehydrogenaseb
[Swiss Prot:
UGDH_HUMAN]
55/66 6.6/6.7 2/4 46 39 11
609 No identified protein /66 /5.9
683 No identified protein /60 /5.8
686 Protein disulphide-isomerase
A3
[Swiss Prot:
PDIA3_HUMAN]
57/59 6.0/6.1 11-11/16-17 1,048-
804
140-106 42-44
694 Protein disulphide-isomerase
A3
[Swiss Prot:
PDIA3_HUMAN]
57/59 6.0/6.3 8-8/14-13 460-362 86-63 38-35
702 No identified protein /59 /7.6
734 T-complex protein 1, subunit
b
[Swiss Prot:
TCPB_HUMAN]
57/57 6.0/6.5 8-12/14-14 503-519 121-121 39-40
852 No identified protein /51 /5.2
877 No identified protein /49 /7.0
918 ANKRD26-like family C
member 1A
[Swiss Prot:
A26CA_HUMAN]
121/47 5.8/5.7 3-4/6-6 242-251 97-107 9-7
Actin cytoplasmic 1 [Swiss Prot:
ACTB_HUMAN]
42/47 5.3/5.7 5/10 390 131 53
Actin cytoplasmic 2 [Swiss Prot:
ACTG_HUMAN]
42/47 5.3/5.7 7/9 418 107 38
953 26S protease regulatory
subunit 8
[Swiss Prot:
PRS8_HUMAN]
46/46 7.1/7.6 9-2/15-7 180-53 41-31 45-21
Mitochondrial import
receptor subunit TOMM40
homolog
[Swiss Prot:
TOM40_HUMAN]
38/46 6.8/7.6 1-1/2-4 48-66 48-38 7-15
Fumarate hydratase
mitochondrial precursorb
[Swiss Prot:
FUMH_HUMAN]
55/46 8.9/7.6 1/3 61 61 7
1108 Nucleophosmin [Swiss Prot:
NPM_HUMAN]
33/39 4.6/5.1 3-4/5-5 83-203 39-65 24-25
1216 Annexin A2 [Swiss Prot:
ANXA2_HUMAN]
39/35 7.6/8.0 11-13/8-10 650-265 99-51 45-38
aMW: molecular weight, pI: isoelectric point, ANKRD26: ankyrin repeat domain-containing protein 26, TOMM40: translocase of outer mitochondrial membrane 40
homolog (yeast). bOnly one peptide of the protein was recognised by matrix-assisted laser desorption ionization time-of-flight/time-of-flight mass spectrometry;
identification spectrum for each protein spot is given in Additional file 5;cindicate number of unique identified peptides in MSMS and in MS+MSMS searches;
didentification was performed twice. When available, both values are given.
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GCA patients, whereas three different proteins were
identified in four pools of sera from GCA patients: actin
cytoplasmic 1, actin cytoplasmic 2 and ANKRD26-like
family C member 1A (Additional file 4, Supplemental
Table S2). Interestingly, IgG from pools of sera from
each of three GCA patients recognised lamin A/C (Fig-
ure 3) and vinculin (Additional file 6).
IgG reactivity against HUVEC protein extracts
The proteome of HUVECs contains 820 different pro-
teins ranging from 3 to 10 IP and from 10 to 250 kDa.
Among these, a mean (± SD) of 515 ± 73 protein spots
were successfully detected after transfer onto PVDF
membranes. Serum IgG from the HC pool recognised
79 protein spots, whereas IgG from the 3 pools of GCA
patients recognised a mean (± SD) of 162 ± 3 protein
spots corresponding to 191 different protein spots. Most
of these 191 protein spots were recognised in only 1
pool of IgG from GCA patients and/or were also recog-
nised in the HC pool. Among these protein spots, 45
were recognised in at least two-thirds of pools from
GCA patients, including 30 that were not recognised in
the HC pool (Additional file 7, Supplemental Table S3).
Of these 30 proteins, 22 were identified by matrix-
assisted laser desorption ionization time-of-flight/time-
of-flight MS. Complete MS data are shown in Table 2.
Localisations of identified protein spots in the analytical
gel are depicted in Figure 4. Overall, three proteins were
recognised by IgG in sera from GCA patients in
HUVEC and VSMC protein extracts: mitochondrial
fumarate hydratase, lamin A/C and vinculin. IgG reac-
tivity against vinculin and lamin A/C in sera from GCA
patients and the HC pool are depicted in Figure 5 and
Additional file 8 respectively.
3 5 7 9
pI
250
173
100
294
683
50 686ど694
852
8771108
1216
953
25
918
342341
340
598
580
15
10
702
609
734
MW
Figure 1 Two-dimensional silver-stained gel of total protein extracted from vascular smooth muscle cells. Localisation of the 19 IgG-
reactive spots recognised by three-fifths of the pools of sera from giant cell arteritis patients. Numbers were arbitrarily assigned by a computer
program. Inset: Enlarged area ranging from 6.5 to 8.2 isoelectric points and 50 to 110 kDa. MW: molecular weight, pI: isoelectric points.
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Biological network analysis of identified autoantibody
specificities
Lists of VSMC and HUVEC proteins specifically recog-
nised and/or recognised with high intensity by IgG in
sera from GCA patients were analysed with IPA. Inter-
estingly, most of the VSMC and HUVEC proteins speci-
fically recognised and/or recognised with high intensity
interacted with growth factor receptor-bound protein 2
(Grb2), a protein involved in VSMC proliferation.
Therefore, we could depict the signalling network
between HUVEC and VSMC proteins identified as
major targets of autoantibodies in patients with GCA
(Figure 6). Interestingly, TNF-a, IL-4 (Figure 6) and
other molecules such as platelet-derived growth factor
and IFN-g (Additional file 9) were also involved in this
signalling network.
Discussion
In the present work, we detected IgG antibodies direc-
ted against the proteome of VSMCs and HUVECs in
the sera of patients with GCA and identified their target
antigens by using a 2-D immunoblotting technique and
MS.
Few studies have focused on perturbations of the
humoral immune system in patients with GCA. Few B
lymphocytes are detected in temporal artery biopsies
from patients with GCA [30]. When present, they are
mainly found in the adventitial layer [31]. Moreover,
plasma cells can be found in the adventitia in 7% to
24% of temporal artery biopsies from patients with GCA
[32]. Plasma cells might localise in adventitia because of
an infectious agent initiating vascular inflammation.
However, a number of studies failed to identify an
A B
P2P1
P3 P4
C
P5 HC
Figure 2 Serum IgG reactivity to far upstream element-binding protein 2 in sera of giant cell arteritis patients. Protein extract is from
vascular smooth muscle cells (VSMCs). (A) IgG reactivity to far upstream element-binding protein 2 (FUBP2) in five different pools of sera from
three giant cell arteritis patients each (P1 to P5) and one pool from twelve healthy controls (HC). (B) FUBP2 spots are expressed in 3-D view for
one representative serum pool of patients (top) and the HC pool (bottom). (C) Proteome of VSMCs showing the localisation of FUBP2 spots
displayed in (A).
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infectious agent, either a virus or bacteria, in the arterial
wall by immunohistochemistry or PCR [33]. Alterna-
tively, an autoantigen present in the arterial wall might
trigger a specific immune response in GCA.
AECAs have been detected in healthy individuals [34]
and in a number of systemic autoimmune diseases
[10,35]. AECAs have been associated with disease activ-
ity in patients with vasculitis, particularly in those with
anti-ANCA-associated vasculitis, Takayasu’s arteritis or
GCA [15], although these data remain controversial
[36]. In addition, AECA could induce EC apoptosis in
patients with systemic sclerosis [37]. However, the
pathogenic role of AECAs has not yet been documented
in GCA, and further investigations are necessary in this
clinical setting.
Although to our knowledge anti-VSMC antibodies
have not yet been reported in a human disease, such
antibodies have been identified in a mouse model of
vasculitis. Baiu et al. [17] showed that splenic mouse
lymphocytes cultured with syngenic VSMCs induced
vasculitic lesions after adoptive transfer into these mice.
Serum collected from mice with vasculitis contained
antibodies directed against VSMCs. Both wild-type and
B-cell-deficient mice showed vascular inflammation after
serum transfer, but mice deficient in both B and T cells
(Rag2-/-) Yes it should did not, which suggests that
immunoglobulin and cell-mediated pathways, particu-
larly T cells, work in concert to contribute to the vascu-
litis lesions in this model. Thus, autoantibodies targeting
proteins in the proteome of VSMCs might play a role in
the pathogenesis of GCA, and their function needs to be
further explored.
Few studies have been conducted to identify the
potential targets of autoantibodies in GCA. Screening
antigens in a cDNA library derived from normal human
testis revealed high-intensity serum IgG reactivity
A B
P1 P2
P3 P4
C
HCP5
Figure 3 Serum IgG reactivity to lamin in serum of giant cell arteritis patients. Protein extract is from vascular smooth muscle cells
(VSMCs). (A) IgG reactivity to lamin in five different pools of sera from three giant cell arteritis patients each (P1 to P5) and one pool from
twelve healthy controls (HC). (B) Lamin spots are expressed in 3-D views for one representative sera pool of giant cell arteritis patients (top) and
the HC pool (bottom). (C) Proteome of VSMCs showing the localisation of lamin spots displayed in (A).
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Table 2 Mass spectrometry data of the endothelial cell protein spots identified as specific target antigensa
Spot
ID
Protein SwissProt
accession
number
Theoretical/
estimated
MW, kDa
Theoretical/
estimated
pI
Number of
unique identified
peptidesc
Total
ion
score
Best
ion
score
Sequence
coverage,
%
228 Vinculin [Swiss Prot:
VINC_HUMAN]
124/116 5.5/6.6 3/13 53 34 15
461 Lamin A/C [Swiss Prot:
LMNA_HUMAN]
74/80 6.6/7.3 11/23 573 82 39
Semaphorin-4D precursor [Swiss Prot:
SEM4D_HUMAN]
96/80 8.3/7.3 2/2 44 29 2
476 Ezrin [Swiss Prot:
EZRI_HUMAN]
69/79 5.9/7.0 2/8 92 58 13
Moesin [Swiss Prot:
MOES_HUMAN]
67/79 6.1/7.0 3/12 186 96 19
Lamin A/C [Swiss Prot:
LMNA_HUMAN]
74/79 6.6/7.0 8/21 314 70 37
Radixin [Swiss Prot:
RADI_HUMAN]
68/79 6.0/7.0 2/6 92 58 10
Semaphorin-4D precursor [Swiss Prot:
SEM4D_HUMAN]
96/79 8.3/7.0 2/2 35 20 2
557 Far upstream element-binding protein
1
[Swiss Prot:
FUBP1_HUMAN]
67/75 7.2/7.2 3/7 114 47 13
631 Lamin A/C [Swiss Prot:
LMNA_HUMAN]
74/71 6.6/6.9 6/10 184 48 15
646 Lamin A/C [Swiss Prot:
LMNA_HUMAN]
74/70 6.6/7.0 12/28 482 71 46
680 No protein identified /66 /8.0
681 No protein identified /66 /8.2
683 No protein identified /66 /8.6
703 No protein identified /65 /5.9
768 No protein identified /60 /7.9
784 Dihydrolipoyl dehydrogenase,
mitochondrial precursor
[Swiss Prot:
DLDH_HUMAN]
54/59 7.6/7.3 2/2 42 22 5
789 Inosine 5’-monophosphate
dehydrogenase 2
[Swiss Prot:
IMDH2_HUMAN]
56/58 6.4/7.1 4/7 169 94 17
853 No protein identified /54 /6
908 a-enolase [Swiss Prot:
ENOA_HUMAN]
47/50 7.0/8.3 7/12 450 143 47
950 Tripeptidyl peptidase 1 precursor [Swiss Prot:
TPP1_HUMAN]
61/50 6.0/6.4 3/5 89 34 15
1017 Fumarate hydratase, mitochondrial
precursor
[Swiss Prot:
FUMH_HUMAN]
55/48 8.9/8.0 6/7 243 71 24
1085 Heterogeneous nuclear
ribonucleoprotein D0
[Swiss Prot:
HNRPD_HUMAN]
38/43 7.6/7.8 3/3 122 69 11
1214 PDZ and LIM domain protein 1 [Swiss Prot:
PDLI1_HUMAN]
36/37 6.6/7.4 5/10 269 62 44
1249 60S acidic ribosomal protein P0 [Swiss Prot:
RLA0_HUMAN]
34/37 5.7/6.0 2/5 56 35 21
1352 Voltage-dependent anion-selective
channel protein 2
[Swiss Prot:
VDAC2_HUMAN]
32/33 7.5/7.4 4/4 155 75 18
1359 Annexin A5 [Swiss Prot:
ANXA5_HUMAN]
36/33 4.9/5.3 10/12 538 86 52
1376 No protein identified /32 /7.5
1440 Heat shock protein b1 [Swiss Prot:
HSPB1_HUMAN]
23/29 6.0/6.2 5/8 382 138 47
NADH dehydrogenase [ubiquinone]
iron-sulphur protein 3, mitochondrial
precursor
[Swiss Prot:
NDUS3_HUMAN]
30/29 7.0/6.2 2/6 70 38 26
1614 Protein DJ-1 [Swiss Prot:
PARK7_HUMAN]
20/25 6.3/6.6 5/5 202 75 51
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directed against a number of ubiquitous autoantigens,
including human lamin C, cytokeratin and mitochon-
drial cytochrome oxidase subunit II in the sera of
patients with GCA [38]. Interestingly, we identified vin-
culin, lamin A/C and mitochondrial fumarate hydratase
as target antigens of antibodies to proteins in the pro-
teome of VSMCs and HUVECs. Vinculin is a cytoskele-
ton protein involved in extracellular matrix adhesion
and intercellular junctions by binding to actin filaments.
This protein has several interaction sites with numerous
Table 2 Mass spectrometry data of the endothelial cell protein spots identified as specific target antigensa (Continued)
1632 No protein identified /23 /5.3
1734 Peptidyl-prolyl cis-trans isomerase A [Swiss Prot:
PPIA_HUMAN]
18/18 7.7/8 3/5 78 48 36
1817 Thioredoxin-dependent peroxide
reductase, mitochondrial precursor
[Swiss Prot:
PRDX3_HUMAN]
28/15 7.7/6.8 5/6 211 61 44
1821 Fatty acid-binding protein, epidermalb [Swiss Prot:
FABP5_HUMAN]
15/15 6.6/6.7 1/5 26 26 47
2120 Elongation factor Tu, mitochondrial
precursor
[Swiss Prot:
EFTU_HUMAN]
50/45 7.3/6.9 5/6 120 58 15
Poly(rC)-binding protein 1b [Swiss Prot:
PCBP1_HUMAN]
37/46 6.7/6.9 1/2 36 36 6
Heterogeneous nuclear
ribonucleoprotein D0b
[Swiss Prot:
HNRPD_HUMAN]
38/45 7.6/6.9 1/4 39 36 10
aMW: molecular weight, PDZ and LIM domain protein 1: postsynaptic density 95 (PSD95), pI: isoelectric point. bOnly one peptide of the protein was recognized
by matrix-assisted laser desorption ionization time-of-flight/time-of-flight mass spectrometry; identification spectrum for each protein spot is given in Additional
file 5. cindicate number of unique identified peptides in MSMS and in MS+MSMS searches.
3 5 7 9
pI
250
100 228
50
1214
1249
25
1440
1359
1376
1352 476
461
631
557
646
1632 1614 703
789
853
784 768
680
681
683
908
1734
15
10
MW
950
1017
2120
1085
18171821
Figure 4 Two-dimensional silver-stained protein pattern of total protein extracted from human umbilical vein endothelial cells.
Localisation of the 30 reactive spots recognised by two-thirds of the pools of sera from giant cell arteritis patients. Numbers were arbitrarily
assigned by a computer program. Inset: Enlarged area ranging from 5.5 to 8.2 isoelectric points and 45 to 90 kDa. MW: molecular weight, pI:
isoelectric points.
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binding partners, including a-actin [39]. Changes in the
relative content of vinculin and a-actin have been
reported in the human aortic intima of patients with
atherosclerosis [40]. Because vascular remodelling may
occur in atherosclerosis, this type of change could be
associated with vascular remodelling in GCA. Lamin A
and C are both encoded by the LMNA gene and repre-
sent major constituents of the inner nuclear membrane.
Mutations in the LMNA gene have been identified in a
number of conditions, including Hutchinson-Gilford
progeria syndrome [41]. The most frequent mutation
responsible for progeria creates a truncated progeria
mutant lamin A (progerin), which accumulates within
the nuclei of human vascular cells and may be directly
responsible for vascular involvement in progeria [42].
Other LMNA gene mutations, such as Dunnigan-type
familial partial lipodystrophy (FPLD2), can lead to
proatherogenic metabolic disturbances such as dyslipide-
mia, hyperinsulinemia, hypertension and diabetes. Pre-
mature atherosclerosis-induced FPLD2 seems to be
associated with monogenic insulin resistance syndrome
[43]. Identification of lamin A/C as target antigens in
A B
P1
P2
C
P3
HC
Figure 5 Serum IgG reactivity to vinculin in serum of patients with giant cell arteritis. (A) IgG reactivities to vinculin in three different
pools of sera from three GCA patients each (P1 to P3) and one pool from twelve healthy controls (HC). (B) Vinculin spots are expressed in 3-D
views for one representative sera pool of patients (top) and the pool of HCs (bottom). (C) Proteome of human umbilical vein endothelial cells
showing the localisation of vinculin spots displayed in (A).
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Figure 6 Pathway generated by ingenuity pathway analysis with proteins identified as specific target antigens. Solid lines indicate
direct interactions. Dashed lines indicate indirect interactions. Arrows indicate stimulation. Mass spectrometry-identified proteins are depicted in
grey. ACTB: actin, b; ACTG1: actin, g1; ANXA2: annexin A2; ANXA5: annexin A5; CCT2: chaperonin containing TCP1, subunit 2 (b); DLD:
dihydrolipoamide dehydrogenase; ENO1: enolase 1, a; EZR: ezrin; FABP5: fatty acid-binding protein 5; FH: fumarate hydratase; GRB2: growth
factor receptor-bound protein 2; HNRNPD: heterogeneous nuclear ribonucleoprotein D; HSP90AA2: heat shock protein 90 a (cytosolic), class A
member 2; HSPB1: HSPB1: heat shock 27-kDa protein 1; IL4: interleukin 4; IMPDH2: IMP (inosine 5’-monophosphate) dehydrogenase; IRS1: insulin
receptor substrate 1; KHSRP: KH-type splicing regulatory protein = FUBP2; LMNA: lamin A/C; MSN: moesin; NPM1: nucleophosmin (nuclear
phosphoprotein B23, numatrin); PDIA3: protein disulphide isomerase, family A, member 3; PPIA: peptidylpropyl isomerase A; PRDX3:
peroxiredoxin 3; RDX: radixin; RPLPO: ribosomal protein, large, P0; SEMA4D: Sema domain, immunoglobulin domain (Ig), transmembrane domain
(TM) and short cytosolic domain (semaphorin) 4D; TNF: tumour necrosis factor; TOMM40: translocase of outer mitochondrial membrane 40
homolog (yeast); TUFM: Tu translation elongation factor, mitochondrial; UGDH: UDP-glucose 6-dehydrogenase; VCL: vinculin; VDAC2: voltage-
dependent anion channel 2.
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sera from patients with GCA seems interesting. Further
investigations are necessary to characterise the implica-
tions of lamin A/C in vascular remodelling in this
condition.
We found another antigen, far upstream element-
binding protein 2 (FUBP = KHSRP), to be recognised by
all five pools of sera from GCA patients in VSMC pro-
tein extracts. This protein, which binds to a DNA region
called far-upstream element (FUSE), is a transcriptional
activator of c-myc, a proto-oncogene that plays a key
role in the regulation of cell growth, proliferation and
differentiation. The FUSE-binding protein (FUBP) regu-
lates FUSE activity [44]. Anti-FUBP antibodies were
identified in synoviocytes in patients with rheumatoid
arthritis, a condition marked by a proliferation of syno-
vial tissue [45]. However, the potential pathogenic role
of these antibodies has not yet been identified.
By using IPA, we found that most of the VSMC and
HUVEC proteins specifically recognised and/or recog-
nised with high intensity by IgG in sera from GCA
patients interacted with Grb2. Grb2 is an intracellular
linker protein that facilitates the activation of the small
GTPase Ras by receptor tyrosine kinases and is involved
in VSMC proliferation. Zhang and colleagues [46]
reported that Grb2 is required for the development of
neointima in response to vascular injury. Thus, Grb2
might be overexpressed and/or activated in ECs and
VSMCs of patients with GCA and might stimulate the
remodelling process. Moreover, proteins overexpressed
in the remodelling process in the presence of activated
Grb2 might trigger a specific immune response, possibly
through structural antigen modifications occurring in
the presence of metalloproteases and/or reactive oxygen
species. A number of the VSMC and HUVEC proteins
specifically recognised and/or recognised with high
intensity by IgG in sera from GCA patients interacted
with TNF-a. This result is in agreement with the patho-
physiology of GCA and the ongoing inflammatory pro-
cess in the arterial wall.
The combined use of 2-DE and immunoblotting offers
an interesting approach to the identification of target
antigens of autoantibodies [25]. However, our work has
several limitations. Fewer than 1,500 protein spots were
stained in the reference gel of VSMC and HUVEC pro-
tein extracts, which is less than the total number of pro-
teins contained in these cells. Therefore, a number of
proteins were probably lost at each step of the techni-
que, depending on their charge, molecular weight, sub-
cellular localisation and/or abundance in the cell. In
addition, as expected, none of the identified antigens
represented cell surface proteins, because protein extrac-
tion for 2-DE does not permit identification of mem-
brane proteins. Finally, our pools of sera were from
three patients each because this number was sufficiently
low to allow the detection of strong reactivity that
would be present in the serum of a single individual
[25]. However, we cannot rule out the possibility that a
low-intensity reactivity specific to a given individual
might not be detected by using this pooling approach.
Conclusions
We provide evidence that IgG antibodies directed
toward the proteome of VSMCs and HUVECs are pre-
sent in the sera of patients with GCA. These antibodies
recognise cellular targets that play key roles in cell biol-
ogy and the maintenance of homeostasis. The potential
pathogenic role of these antibodies should be further
investigated.
Additional material
Additional file 1: Supplemental file. Detailed data concerning 2-D
electrophoresis technique and mass spectrometry identification [47-49].
Additional file 2: Supplemental Table S1. Clinical and histological
characteristics of 15 patients with giant cell arteritis.
Additional file 3: Supplemental Figure S1. One-dimensional
immunoblot IgG reactivity from giant cell arteritis patients with vascular
smooth muscle cell proteins. Serum samples from three patients with
GCA were tested, and sera from four patients with Wegener’s
granulomatosis (WG), two with Churg-Strauss syndrome (CSS) and two
with microscopic polyangeitis (MPA) used as vasculitis controls,
intravenous immunoglobulin (IVIg) as a positive control and PBS and sera
from two healthy controls (HCs) as negative controls were
immunoblotted at a dilution of 1:100 with a soluble extract of
immortalised human mammary artery VSMCs.
Additional file 4: Supplemental Table S2. Antigens specifically
recognised by IgG of three-fifths of the pools of sera from giant cell
arteritis patients.
Additional file 5: Mass spectrometry data of target antigens
recognised by only one peptide.
Additional file 6: Supplemental Figure S2. 2-D immunoblots of IgG
reactivity to vinculin in sera from patients with giant cell arteritis.
Protein extract is from vascular smooth muscle cells (VSMCs). (A) IgG
reactivities of five different pools of sera from three giant cell arteritis
patients each (P1 to P5) and one pool from twelve healthy controls
(HCs). (B) Vinculin spots are expressed in 3-D views for one
representative sera pool of patients (top) and the HC pool (bottom). (C)
Proteome of VSMCs showing the localisation of vinculin spots displayed
in (A).
Additional file 7: Supplemental Table S3. Antigens specifically
recognised by IgG of two-thirds of the pools of sera from giant cell
arteritis patients.
Additional file 8: Supplemental Figure S3. Two-dimensional
immunoblots of IgG reactivity to lamin in sera of patients with
giant cell arteritis. Protein extract is from human umbilical vein
endothelial cells (HUVECs). (A) IgG reactivities to lamin of three
different pools of sera from three giant cell arteritis patients each (P1 to
P3) and one pool from twelve healthy controls (HCs). (B) Lamin spots are
expressed in 3-D views for one representative sera pool from patients
(top) and the HC pool (bottom). (C) Proteome of HUVECs showing the
localisation of lamin spots displayed in (A).
Additional file 9: Supplement Figure S4. Protein network generated
by merging the two pathways involved in target antigens. Protein
extracts are from human umbilical vein endothelial cells and vascular
smooth muscle cells. Solid lines indicate direct interactions. Dashed lines
indicate indirect interactions. Arrows indicate stimulation. ABCA2: ATP-
binding cassette, subfamily A, (ABC1), member 2; ACTB: actin, b; ACTG1:
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actin, g1; ANXA2: annexin A2; ANXA5: annexin A5; CCND2: cyclin D2;
CCT2: chaperonin containing TCP1, subunit 2 (b); COPA: coatomer
protein complex, subunit a; CPOX: coproporphyrinogen oxidase; DLD:
dihydrolipoamide dehydrogenase; ENO1: enolase 1, a; EZR: ezrin; FABP5:
fatty acid-binding protein 5; FH: fumarate hydratase; FUBP1: far upstream
element (FUSE)-binding protein 1; GRB2: growth factor receptor-bound
protein 2; HNRNPD: heterogeneous nuclear ribonucleoprotein D;
HSP90AA2: heat shock protein 90 kDa a (cytosolic), class A, member 2;
HSPB1: heat shock 27-kDa protein 1; IFNG: interferon g; IKBKG: inhibitor of
 light polypeptide gene enhancer in B cells, kinase g; IL4: interleukin 4;
IMPDH2: IMP (inosine 5’-monophosphate) dehydrogenase; IRS1: insulin
receptor substrate 1; KHSRP: KH-type splicing regulatory protein; LMNA:
lamin A/C; MSN: moesin; NDUFS3: NADH dehydrogenase (ubiquinone)
iron-sulphur protein 3, 30 kDa (NADH coenzyme Q reductase); NPM1:
nucleophosmin (nuclear phosphoprotein B23, numatrin); PARK7:
Parkinson’s disease (autosomal recessive early onset) 7; PDGF BB: platelet-
derived growth factor B dimer; PDIA3: protein disulphide isomerase,
family A, member 3; PHB: prohibitin; PPIA: peptidylpropyl-isomerase A;
PRDX3: peroxiredoxin 3; PSMC5: proteasome 26S subunit, ATPase, 5; RDX:
radixin; RPLPO: ribosomal protein, large, P0; SEMA4D: Sema domain,
immunoglobulin domain (Ig), transmembrane domain (TM) and short
cytosolic domain (semaphorin) 4D; TNF: tumour necrosis factor; TOMM40:
translocase of outer mitochondrial membrane 40 homolog (yeast); TP53:
tumour protein P53; TPP1: tripeptidyl 1 peptidase; TUFM: Tu translation
elongation factor, mitochondrial; UGDH: UDP-glucose 6-dehydrogenase;
VCL: vinculin; VDAC2: voltage-dependent anion channel 2.
Abbreviations
ACR: American College of Rheumatology; AECA: anti-endothelial cell
antibody; ANCA: antineutrophil cytoplasm antibody; bFGF: basic fibroblast
growth factor; CSS: Churg-Strauss syndrome; EC: endothelial cell; EGF:
epidermal growth factor; ELISA: enzyme-linked immunosorbent assay; FCS:
foetal calf serum; FUBP2: far upstream element-binding protein 2; FUSE: far
upstream element; GCA: giant cell arteritis; Grb2: growth factor receptor-
bound protein 2; HC: healthy control; HUVEC: human umbilical vein
endothelial cell; IFN-γ: interferon-γ; IL: interleukin; IP: isoelectrofocalisation
point; IPA: ingenuity pathway analysis; IPKB: Ingenuity Pathway
Knowledgebase; MPA: microscopic polyangiitis; MS: mass spectrometry;
PMSF: phenylmethylsulphonyl fluoride; PVDF: polyvinylidene fluoride; RT:
reverse transcriptase; TNF-α: tumour necrosis factor α; VSMC: vascular
smooth muscle cell; WG: Wegener’s granulomatosis.
Acknowledgements
AR received financial support from the Direction Régionale et
départementale de Champagne-Ardennes et de la Marne and the Société
Nationale Française de Médecine Interne (SNFMI). HD received financial
support from Avenir Mutualiste des Professions Libérales & Indépendantes
(AMPLI) and Association pour la Recherche en Médecine Interne et en
Immunologie Clinique (ARMIIC). KHL received financial support from
Limoges Hospital. MCT received a grant from Pfizer and the Direction de la
Recherche Clinique (PHRC National Auto-HTAP). We also thank the Unité de
Recherche Clinique Cochin-Necker. We also thank CSL Behring for financial
support. None of the funding bodies had a role in the study design; the
collection, analysis or interpretation of data; the writing of the manuscript; or
the decision to submit the manuscript for publication.
Author details
1Inserm U1016, Institut Cochin, CNRS UMR 8104, 8 rue Méchain, F-75014
Paris, France. 2Université Paris Descartes, 12 rue de l’Ecole de Médecine, F-
75270 Paris, France. 3Pôle de Médecine Interne, Centre de Référence pour
les vascularites nécrosantes et la sclérodermie systémique, Hôpital Cochin,
Assistance Publique Hôpitaux de Paris, 27 rue du Faubourg Saint-Jacques, F-
75679 Paris Cedex 14 Paris, France. 4Service de Médecine Interne A, CHU
Dupuytren, 2 avenue Martin Luther King, F-87042 Limoges cedex 1, France.
5Service de Médecine Interne, hôpital Hôtel Dieu, Place Alexis Ricordeau, F-
44093 Nantes cedex 1, France. 6Weill Medical College of Cornell University,
1300 York Avenue, New York, NY 10065, USA. 7Institut Cochin, Plate-forme
Protéomique de l’Université Paris Descartes, CNRS UMR 8104, 8 rue Méchain,
F-75014 Paris, France.
Authors’ contributions
AR carried out the immunoblotting and proteomic experiments, analysed
the results and drafted the manuscript. HD carried out immunoblotting and
proteomic experiments with AR, participated in the analysis of the results
and edited the manuscript. KHL carried out 1-D immunoblotting
experiments and participated in the drafting of the manuscript. CA
conducted the inclusion of patients into the study, analysed the results and
edited the manuscript. MCT participated in the study design and the
analysis of the results and also edited the manuscript. NT participated in
immunoblotting and proteomic experiments, participated in the analysis of
the results and edited the manuscript. CF performed ingenuity pathway
analysis, participated in the analysis of the results and edited the manuscript.
CB performed proteomic analysis, participated in the analysis of the results
and edited the manuscript. BW provided immortalised VSMCs, participated
in the analysis of the results and edited the manuscript. LG provided sera
from patients, participated in the study design and analysis of the results
and also edited the manuscript. LM provided sera from patients, designed
the experiments, analysed the results and drafted the manuscript. All authors
read and approved the final manuscript.
Competing interests
AR, HD and LM have applied for a patent related to the content of this
article (Patent Procédé de diagnostic d’une vascularite FR0951205).
Received: 25 February 2011 Revised: 15 May 2011
Accepted: 28 June 2011 Published: 28 June 2011
References
1. Hunder GG: Epidemiology of giant-cell arteritis. Cleve Clin J Med 2002,
69(Suppl 2):SII79-SII82.
2. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA,
Gonzalez-Juanatey C, Martin J, Llorca J: Epidemiology of giant cell arteritis
and polymyalgia rheumatica. Arthritis Rheum 2009, 61:1454-1461.
3. González-Gay MA, Blanco R, Rodríguez-Valverde V, Martínez-Taboada VM,
Delgado-Rodriguez M, Figueroa M, Uriarte E: Permanent visual loss and
cerebrovascular accidents in giant cell arteritis: predictors and response
to treatment. Arthritis Rheum 1998, 41:1497-1504.
4. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH,
Edworthy SM, Fauci AS, Leavitt RY, Lie JT, Lightfoot RW Jr, Masi AT,
McShane DJ, Mills JA, Wallace SL, Zvaifler NJ: The American College of
Rheumatology 1990 criteria for the classification of giant cell arteritis.
Arthritis Rheum 1990, 33:1122-1128.
5. Hall S, Persellin S, Lie JT, O’Brien PC, Kurland LT, Hunder GG: The
therapeutic impact of temporal artery biopsy. Lancet 1983, 2:1217-1220.
6. Ly KH, Regent A, Tamby MC, Mouthon L: Pathogenesis of giant cell
arteritis: more than just an inflammatory condition? Autoimmun Rev 2010,
9:635-645.
7. Brack A, Geisler A, Martinez-Taboada VM, Younge BR, Goronzy JJ,
Weyand CM: Giant cell vasculitis is a T cell-dependent disease. Mol Med
1997, 3:530-543.
8. Rittner HL, Kaiser M, Brack A, Szweda LI, Goronzy JJ, Weyand CM: Tissue-
destructive macrophages in giant cell arteritis. Circ Res 1999,
84:1050-1058.
9. Rodríguez-Pla A, Bosch-Gil JA, Rosselló-Urgell J, Huguet-Redecilla P,
Stone JH, Vilardell-Tarres M: Metalloproteinase-2 and -9 in giant cell
arteritis: involvement in vascular remodeling. Circulation 2005,
112:264-269.
10. Guilpain P, Mouthon L: Antiendothelial cells autoantibodies in vasculitis-
associated systemic diseases. Clin Rev Allergy Immunol 2008, 35:59-65.
11. Hu N, Westra J, Huitema MG, Stegeman CA, Limburg PC, Kallenberg CG:
Autoantibodies against glomerular endothelial cells in anti-neutrophil
cytoplasmic autoantibody-associated systemic vasculitis. Nephrology
(Carlton) 2009, 14:11-15.
12. Holmén C, Christensson M, Pettersson E, Bratt J, Stjärne P, Karrar A,
Sumitran-Holgersson S: Wegener’s granulomatosis is associated with
organ-specific antiendothelial cell antibodies. Kidney Int 2004,
66:1049-1060.
Régent et al. Arthritis Research & Therapy 2011, 13:R107
http://arthritis-research.com/content/13/3/R107
Page 13 of 15
13. Holmén C, Elsheikh E, Christensson M, Liu J, Johansson AS, Qureshi AR,
Jalkanen S, Sumitran-Holgersson S: Anti endothelial cell autoantibodies
selectively activate SAPK/JNK signalling in Wegener’s granulomatosis. J
Am Soc Nephrol 2007, 18:2497-2508.
14. van Paassen P, Duijvestijn A, Debrus-Palmans L, Damoiseaux J, Vroomen M,
Tervaert JW: Induction of endothelial cell apoptosis by IgG antibodies
from SLE patients with nephropathy: a potential role for anti-endothelial
cell antibodies. Ann N Y Acad Sci 2007, 1108:147-156.
15. Navarro M, Cervera R, Font J, Reverter JC, Monteagudo J, Escolar G, López-
Soto A, Ordinas A, Ingelmo M: Anti-endothelial cell antibodies in systemic
autoimmune diseases: prevalence and clinical significance. Lupus 1997,
6:521-526.
16. Amor-Dorado JC, García-Porrua C, Gonzalez-Gay MA: Anti-endothelial cell
antibodies and biopsy-proven temporal arteritis. Lupus 2002, 11:134.
17. Baiu DC, Barger B, Sandor M, Fabry Z, Hart MN: Autoantibodies to vascular
smooth muscle are pathogenic for vasculitis. Am J Pathol 2005,
166:1851-1860.
18. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC,
Hoffman GS, Hunder GG, Kallenberg CGM, McCluskey RT, Sinico RA, Rees AJ,
Van Es LA, Waldherr R, Wiik A: Nomenclature of systemic vasculitides:
proposal of an international consensus conference. Arthritis Rheum 1994,
37:187-192.
19. Weksler BB, Subileau EA, Perrière N, Charneau P, Holloway K, Leveque M,
Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F,
Greenwood J, Romero IA, Couraud PO: Blood-brain barrier-specific
properties of a human adult brain endothelial cell line. FASEB J 2005,
19:1872-1874.
20. Ronda N, Leonardi S, Orlandini G, Gatti R, Bellosta S, Bernini F, Borghetti A:
Natural anti-endothelial cell antibodies (AECA). J Autoimmun 1999,
13:121-127.
21. Tamby MC, Chanseaud Y, Humbert M, Fermanian J, Guilpain P, Garcia-de-la-
Peña-Lefebvre P, Brunet S, Servettaz A, Weill B, Simonneau G, Guillevin L,
Boissier MC, Mouthon L: Anti-endothelial cell antibodies in idiopathic and
systemic sclerosis associated pulmonary arterial hypertension. Thorax
2005, 60:765-772.
22. García de la Peña-Lefebvre P, Chanseaud Y, Tamby MC, Reinbolt J,
Batteux F, Allanore Y, Kahan A, Meyer O, Benveniste O, Boyer O, Guillevin L,
Boissier MC, Mouthon L: IgG reactivity with a 100-kDa tissue and
endothelial cell antigen identified as topoisomerase 1 distinguishes
between limited and diffuse systemic sclerosis patients. Clin Immunol
2004, 111:241-251.
23. Tamby MC, Bussone G, Mouthon L: Antitopoisomerase 1 antibodies in
systemic sclerosis: how to improve the detection? Ann N Y Acad Sci 2007,
1109:221-228.
24. Chanseaud Y, García de la Peña-Lefebvre P, Guilpain P, Mahr A, Tamby MC,
Uzan M, Guillevin L, Boissier MC, Mouthon L: IgM and IgG autoantibodies
from microscopic polyangiitis patients but not those with other small-
and medium-sized vessel vasculitides recognize multiple endothelial cell
antigens. Clin Immunol 2003, 109:165-178.
25. Terrier B, Tamby MC, Camoin L, Guilpain P, Broussard C, Bussone G, Yaïci A,
Hotellier F, Simonneau G, Guillevin L, Humbert M, Mouthon L:
Identification of target antigens of antifibroblast antibodies in
pulmonary arterial hypertension. Am J Respir Crit Care Med 2008,
177:1128-1134.
26. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with
the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
27. Guilpain P, Servettaz A, Tamby MC, Chanseaud Y, Tamas N, Garcia de la
Pena-Lefebvre P, Broussard C, Guillevin L, Camoin L, Mouthon L: A
combined SDS-PAGE and proteomics approach to identify target
autoantigens in healthy individuals and patients with autoimmune
diseases. Ann N Y Acad Sci 2007, 1109:538-549.
28. Bussone G, Dib H, Tamby MC, Broussard C, Federici C, Woimant G,
Camoin L, Guillevin L, Mouthon L: Identification of new autoantibody
specificities directed at proteins involved in the transforming growth
factor β pathway in patients with systemic sclerosis. Arthritis Res Ther
2011, 13:R74.
29. Qi YX, Jiang J, Jiang XH, Wang XD, Ji SY, Han Y, Long DK, Shen BR, Yan ZQ,
Chien S, Jiang ZL: PDGF-BB and TGF-β1 on cross-talk between
endothelial and smooth muscle cells in vascular remodeling induced by
low shear stress. Proc Natl Acad Sci USA 2011, 108:1908-1913.
30. Banks PM, Cohen MD, Ginsburg WW, Hunder GG: Immunohistologic and
cytochemical studies of temporal arteritis. Arthritis Rheum 1983,
26:1201-1207.
31. Lavignac C, Jauberteau-Marchan MO, Liozon E, Vidal E, Catanzano G,
Liozon F: Immunohistochemical study of lesions in Horton’s temporal
arteritis before and during corticotherapy in French. Rev Med Interne
1996, 17:814-820.
32. Chatelain D, Duhaut P, Loire R, Bosshard S, Pellet H, Piette JC, Sevestre H,
Ducroix JP: Small-vessel vasculitis surrounding an uninflamed temporal
artery: a new diagnostic criterion for polymyalgia rheumatica? Arthritis
Rheum 2008, 58:2565-2573.
33. Duhaut P, Bosshard S, Ducroix JP: Is giant cell arteritis an infectious
disease? Biological and epidemiological evidence. Presse Med 2004,
33:1403-1408.
34. Servettaz A, Guilpain P, Camoin L, Mayeux P, Broussard C, Tamby MC,
Tamas N, Kaveri SV, Guillevin L, Mouthon L: Identification of target
antigens of antiendothelial cell antibodies in healthy individuals: a
proteomic approach. Proteomics 2008, 8:1000-1008.
35. Domiciano DS, Carvalho JF, Shoenfeld Y: Pathogenic role of anti-
endothelial cell antibodies in autoimmune rheumatic diseases. Lupus
2009, 18:1233-1238.
36. Del Papa N, Guidali L, Sironi M, Shoenfeld Y, Mantovani A, Tincani A,
Balestrieri G, Radice A, Sinico RA, Meroni PL: Anti-endothelial cell IgG
antibodies from patients with Wegener’s granulomatosis bind to human
endothelial cells in vitro and induce adhesion molecule expression and
cytokine secretion. Arthritis Rheum 1996, 39:758-766.
37. Bordron A, Dueymes M, Levy Y, Jamin C, Leroy JP, Piette JC, Shoenfeld Y,
Youinou PY: The binding of some human antiendothelial cell antibodies
induces endothelial cell apoptosis. J Clin Invest 1998, 101:2029-2035.
38. Schmits R, Kubuschok B, Schuster S, Preuss KD, Pfreundschuh M: Analysis of
the B cell repertoire against autoantigens in patients with giant cell
arteritis and polymyalgia rheumatica. Clin Exp Immunol 2002, 127:379-385.
39. Ziegler WH, Liddington RC, Critchley DR: The structure and regulation of
vinculin. Trends Cell Biol 2006, 16:453-460.
40. Glukhova MA, Kabakov AE, Frid MG, Ornatsky OI, Belkin AM, Mukhin DN,
Orekhov AN, Koteliansky VE, Smirnov VN: Modulation of human aorta
smooth muscle cell phenotype: a study of muscle-specific variants of
vinculin, caldesmon, and actin expression. Proc Natl Acad Sci USA 1988,
85:9542-9546.
41. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR,
Robbins CM, Moses TY, Berglund P, Dutra A, Pak E, Durkin S, Csoka AB,
Boehnke M, Glover TW, Collins FS: Recurrent de novo point mutations in
lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003,
423:293-298.
42. McClintock D, Gordon LB, Djabali K: Hutchinson-Gilford progeria mutant
lamin A primarily targets human vascular cells as detected by an anti-
lamin A G608G antibody. Proc Natl Acad Sci USA 2006, 103:2154-2159.
43. Hegele RA: Premature atherosclerosis associated with monogenic insulin
resistance. Circulation 2001, 103:2225-2229.
44. Duncan R, Bazar L, Michelotti G, Tomonaga T, Krutzsch H, Avigan M,
Levens D: A sequence-specific, single-strand binding protein activates
the far upstream element of c-myc and defines a new DNA-binding
motif. Genes Dev 1994, 8:465-480.
45. Goëb V, Thomas-L’Otellier M, Daveau R, Charlionet R, Fardellone P, Le
Loët X, Tron F, Gilbert D, Vittecoq O: Candidate autoantigens identified by
mass spectrometry in early rheumatoid arthritis are chaperones and
citrullinated glycolytic enzymes. Arthritis Res Ther 2009, 11:R38.
46. Zhang S, Ren J, Khan MF, Cheng AM, Abendschein D, Muslin AJ: Grb2 is
required for the development of neointima in response to vascular
injury. Arterioscler Thromb Vasc Biol 2003, 23:1788-1793.
47. García de la Peña-Lefebvre P, Chanseaud Y, Tamby MC, Reinbolt J,
Batteux F, Allanore Y, Kahan A, Meyer O, Benveniste O, Boyer O, Guillevin L,
Boissier MC, Mouthon L: IgG reactivity with a 100-kDa tissue and
endothelial cell antigen identified as topoisomerase 1 distinguishes
between limited and diffuse systemic sclerosis patients. Clin Immunol
2004, 111:241-251.
48. Shevchenko A, Wilm M, Vorm O, Mann M: Mass spectrometric sequencing
of proteins silver-stained polyacrylamide gels. Anal Chem 1996,
68:850-858.
Régent et al. Arthritis Research & Therapy 2011, 13:R107
http://arthritis-research.com/content/13/3/R107
Page 14 of 15
49. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS: Probability-based protein
identification by searching sequence databases using mass
spectrometry data. Electrophoresis 1999, 20:3551-3567.
doi:10.1186/ar3388
Cite this article as: Régent et al.: Identification of target antigens of
anti-endothelial cell and anti-vascular smooth muscle cell antibodies in
patients with giant cell arteritis: a proteomic approach. Arthritis Research
& Therapy 2011 13:R107.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Régent et al. Arthritis Research & Therapy 2011, 13:R107
http://arthritis-research.com/content/13/3/R107
Page 15 of 15
